The short version of GHRH analog fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-24. Anything still debated is marked as such rather than presented as settled.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Carbonyl sulfide is the chemical compound with the linear formula O=C=S. It is a colorless flammable gas with an unpleasant odor. It is a linear molecule consisting of a carbonyl double bonded to a sulfur atom. Carbonyl sulfide can be considered to be intermediate between carbon dioxide and carbon disulfide, both of which are valence isoelectronic with it.
Diffusion force caused by a concentration gradient - all particles tend to diffuse from higher concentration to lower. Electrostatic force caused by electrical potential gradient - cations like protons H+ tend to diffuse down the electrical potential, from the positive (P) side of the membrane to the negative (N) side. Anions diffuse spontaneously in the opposite direction. These two gradients taken together can be expressed as an electrochemical gradient. Lipid bilayers of biological membranes, however, are barriers for ions. This is why energy can be stored as a combination of these two gradients across the membrane. Only special membrane proteins like ion channels can sometimes allow ions to move across the membrane (see also: Membrane transport). In the chemiosmotic hypothesis a transmembrane ATP synthase is central to convert energy of spontaneous flow of protons through them into chemical energy of ATP bonds. Hence researchers created the term proton-motive force (PMF), derived from the electrochemical gradient mentioned earlier. It can be described as the measure of the potential energy stored (chemiosmotic potential) as a combination of proton and voltage (electrical potential) gradients across a membrane. The electrical gradient is a consequence of the charge separation across the membrane (when the protons H+ move without a counterion, such as chloride Cl−).
==== Subepidermal calcified nodule ==== Subepidermal calcified nodule is characterized by calcification of the skin resulting from the deposition of calcium and phosphorus, occurring most frequently as one or a few skin lesions on the scalp or face of children.
Sources: en.wikipedia.org
On June 24, Caldwell Dyson participated as a crew member for EVA 90 with Michael Barratt. Unfortunately, this EVA ended early due to a water leak in the service and cooling umbilical unit on Caldwell-Dyson’s spacesuit. The leak came from the SCU when Caldwell-Dyson disconnected her SCU from her EMU after she switched to battery power. The total EVA time was only 31 minutes. All of their EVAs were postponed to a later date after the incident, and Expedition 71 remained focused on their scientific work, cargo vehicle traffic, and maintenance tasks. More specifically, they saw the departure of Cygnus NG-20 named after Dyson's classmate: Patricia Hilliard Robertson on July 12th and the arrival of Cygnus NG-21 - Francis Scobee on August 6th. Caldwell Dyson spent six months on the station and returned on September 23, 2024 with Oleg Kononenko and Nikolai Chub on the Soyuz MS-25 spacecraft.
== Production == In January 1995, it was reported that 20th Century Fox had secured deals with Keanu Reeves and Andrew Davis to star in and direct respectively the action thriller Dead Drop. Reeves was reportedly paid $7 million upfront against at least 5% of first-dollar gross for his role while Davis was reportedly paid $5 million. Large portions of the film were shot on location in and around Chicago, Illinois, including the University of Chicago, Argonne National Laboratory, the Museum of Science and Industry, the Field Museum of Natural History, Michigan Avenue, and the James R. Thompson Center (Atrium Mall). Additional scenes were shot at Yerkes Observatory in Williams Bay, Wisconsin, on Geneva Lake in southern Wisconsin, interiors of the U.S. Capitol were shot at the Wisconsin State Capitol, in Madison, Wisconsin, at Inland Steel Company (now known as Cleveland-Cliffs Inc.) in East Chicago, Indiana, and at a private residence in Barrington Hills, Illinois. Because of the cold Great Lakes winter and filming taking place during record-breaking winter weather, unique challenges were present for the cast and crew. Morgan Freeman noted "It was difficult for everyone, particularly for me because I'm tropical," he said. "I don't do cold weather. This is Chicago...in the winter. I was ill and in bed [for] four days at a crack. It was really rough."
== Long Range Patrol – Improved == While the MRE was lighter than the canned MCI and had more dietary energy than the LRP ration, it had certain problems. US Special Operations forces found it too bulky, and troops on maneuvers found some menu items were unsuited for easy digestion in cold-weather, high-altitude, high-temperature, or humid environments. While unofficial practice was to strip out items deemed "unnecessary", this also reduced the ration's dietary energy content. Faced with these problems, this forced the adoption of a specialized ration for light troops or commando units on extended field operations. In 1994, a new version of the LRP called the Food Packet, Long-Range Patrol – Improved (LRP-I) was created. It was an 11-ounce (310 g) ration that came in a brown plastic retort pouch that allowed the user to reconstitute and cook the ration directly in the pouch. This was an improvement over the earlier LRP packet, which had to be boiled or soaked in a canteen cup or other cookware.
=== Minor leagues (1949–51) === Mizell's first team was the Albany Cardinals of the Class D Georgia–Florida League. His first pitch for the team sailed 20 feet over the backstop. Overcoming homesickness, he went on to help Albany win the pennant. He had a 12–3 record and a 1.95 earned run average (ERA) for Albany, recording 175 strikeouts in 141 innings pitched. Promoted to the Class B Winston-Salem Cardinals of the Carolina League in 1950, Mizell got off to a 1–6 start. However, he went on to post a 17–7 record, finishing tied (with Wes Livengood) for fourth in the Carolina League in wins and second (behind Woody Rich) in ERA with a 2.48 mark. He struck out 227 batters in 207 innings, leading Winston-Salem to a championship. In the last game of the season, he hit a home run, the only professional one of his career, which he referred to as a $220 home run because fans passed a hat around and donated that sum in appreciation of his efforts. One night during the season, he sang country music over the public address system at South Side Park and rode around the field on a mule. In 1951, Mizell pitched for the Houston Buffaloes of the Class AA Texas League. The team held a "Vinegar Bend Night," flying in 32 visitors reportedly from the town in Alabama for the evening's game. Because the town was so small, Mizell said that some of the guests "must've come from the suburbs." He had 15 strikeouts in that game, a 3–1 loss to the Shreveport Sports. In another outing, against the Dallas Eagles, he struck out 18 batters, tying the league's single-game record.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.